Ilaria Platè

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study

Daniele Lini, Matteo Colina, Romina Andracco, Francesca Ometto et autres

Objective: To evaluate the real-world effectiveness of baricitinib (BARI) in rheumatoid arthritis (RA), compare outcomes in patients Methods: Retrospective multicentre cohort (n=423). Baseline variables included age, sex, disease duration, and comorbidities. DAS28-ESR was recorded at baseline, 6 and 12 months; remission was …

it (code pays fourni par la source)

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort

Eleonora Celletti, Myriam Di Penta, Alarico Ariani, Simone Parisi et autres

The efficacy and safety of filgotinib (FIL) for the treatment of patients with rheumatoid arthritis (RA) have been evaluated in a number of randomized controlled trials. However, there is a scarcity of real-world studies evaluating the effectiveness, persistence, tolerability, and safety of …

it, us (code pays fourni par la source)

Comparative effectiveness of cycling versus swapping to IL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real-world multicenter study

Alarico Ariani, Maddalena Larosa, Alberto Lo Gullo, Olga Addimanda et autres

OBJECTIVE: The increase in biological disease-modifying antirheumatic drugs for psoriatic arthritis (PsA) made it possible to consider different mechanisms of action (MoA) after the failure of the first advanced-line therapy. However, there is still a lack of real-world evidence comparing the cycling …

it, us (code pays fourni par la source)

ABS0436 APREMILAST VS ADALIMUMAB EFFECTIVENESS IN BIOLOGIC-NAIVE PsA

C. Castellani, Olga Addimanda, M. Reta, Mauro Magnani et autres

Background: Both Apremilast (APR) and Adalimumab (ADA) are well known therapeutical strategies for the management of psoriatic arthritis (PsA) [1]. There are no direct effectiveness (i.e. survival rates) comparison between such therapies in biologic-naïve PsA patients. Objectives: To compare APR and ADA …

us, it (code pays fourni par la source)

ABS0668 MULTICENTER OBSERVATIONAL STUDY ON THE EFFICACY OF GUSELKUMAB IN PSORIATIC ARTHRITIS

Alberto Lo Gullo, Silvia Parisi, A. Becciolini, Marino Paroli et autres

Background: Guselkumab (GUS) is an interleukin IL-23 inhibitor which has been proven effective in treating patients with psoriatic arthritis (psA). Objectives: The purpose of this study was to determine the efficacy of GUS to obtain remission or low disease activity (LDA) in …

it, us (code pays fourni par la source)

Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study

Camilla Mazzanti, Marino Paroli, Gianluca Santoboni, Olga Addimanda et autres

IXE (Ixekizumab) is a monoclonal antibody targeting interleukin-17A (IL17A) which has demonstrated significant efficacy and safety in the management of psoriatic arthritis (PsA) in randomized controlled trials (RCTs). However, available data on long-term persistence of therapy are scarce. Methods: This multi-center study …

it (code pays fourni par la source)

Guselkumab effectiveness in real-world settings: observations from an Italian multicentre study

Andrea Becciolini, Antonio Marchesoni, Simone Parisi, Alberto Lo Gullo et autres

Abstract Objectives Guselkumab is a biologic disease-modifying antirheumatic drug (bDMARD) with proven efficacy for psoriatic arthritis (PsA) in randomized controlled trials. Evidence of its effectiveness from clinical practice remains limited. We evaluated the real-world effectiveness of guselkumab for PsA (primary objective) and …

it, us, gb (code pays fourni par la source)

Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup—A Multicenter Study

Marta Priora, Andrea Becciolini, Eleonora Celletti, Myriam Di Penta et autres

Background and Objectives: The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients who have failed or are intolerant to conventional synthetic …

it (code pays fourni par la source)

Baseline Ultrasound Assessment Improves the Response to Apremilast in Patients with Psoriatic Arthritis: Results from a Multicentre Study

Antonella Farina, Patrizia Del Medico, Simone Parisi, Andrea Becciolini et autres

Background: Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important to choose the most effective treatment according to patients' characteristics. Apremilast is recommended in PsA with moderate activity. In clinical practice, the …

it (code pays fourni par la source)

Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in Italy

Marino Paroli, Andrea Becciolini, Alberto Lo Gullo, Simone Parisi et autres

Background/Objectives: The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, the US Food and Drug Administration (FDA) raised concerns about the safety of TOFA after its approval. …

it (code pays fourni par la source)

Retention rate of upadacitinib therapy in rheumatoid arthritis: Results of a large Italian multicenter real-world study

Palma Scolieri, Andrea Becciolini, Alarico Ariani, Elena Bravi et autres

Introduction: Upadacitinib (UPA) is an oral Janus kinase inhibitor (JAKi) recently approved for the treatment rheumatoid arthritis (RA) treatment. Although registrational studies have demonstrated the efficacy of UPA in RA, data on the long-term retention rate of this drug are still lacking. …

it (code pays fourni par la source)

POS0266 CYCLING VS SWAP TNFi AND IL17i IN PSORIATIC ARTHRITIS: RESULTS FROM THE BIRRA RETROSPECTIVE OBSERVATIONAL STUDY

Alarico Ariani, Federica Lumetti, Simone Parisi, Olga Addimanda et autres

it, us (code pays fourni par la source)